CA2515328A1 - Use of omega-3-fatty acids in the treatment of diabetic patients - Google Patents
Use of omega-3-fatty acids in the treatment of diabetic patients Download PDFInfo
- Publication number
- CA2515328A1 CA2515328A1 CA002515328A CA2515328A CA2515328A1 CA 2515328 A1 CA2515328 A1 CA 2515328A1 CA 002515328 A CA002515328 A CA 002515328A CA 2515328 A CA2515328 A CA 2515328A CA 2515328 A1 CA2515328 A1 CA 2515328A1
- Authority
- CA
- Canada
- Prior art keywords
- epa
- dha
- diabetes
- medicament
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03004792.2 | 2003-03-05 | ||
EP03004792 | 2003-03-05 | ||
PCT/EP2004/050238 WO2004078166A2 (en) | 2003-03-05 | 2004-03-02 | Use of omega-3-fatty acids in the treatment of diabetic patients |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2515328A1 true CA2515328A1 (en) | 2004-09-16 |
Family
ID=32946844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002515328A Abandoned CA2515328A1 (en) | 2003-03-05 | 2004-03-02 | Use of omega-3-fatty acids in the treatment of diabetic patients |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1603551A2 (ja) |
JP (1) | JP2006519244A (ja) |
CN (1) | CN1756545A (ja) |
AU (1) | AU2004216856A1 (ja) |
BR (1) | BRPI0408006A (ja) |
CA (1) | CA2515328A1 (ja) |
MX (1) | MXPA05009432A (ja) |
WO (1) | WO2004078166A2 (ja) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
JP4954714B2 (ja) * | 2005-01-04 | 2012-06-20 | 持田製薬株式会社 | 脂肪毒性の改善剤 |
CN101213281B (zh) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
AU2006242914B2 (en) | 2005-05-04 | 2012-02-02 | Pronova Biopharma Norge As | New DHA derivatives and their use as medicaments |
KR101255650B1 (ko) * | 2005-05-04 | 2013-04-16 | 프로노바 바이오파마 너지 에이에스 | 새로운 dha 유도체 및 약제로서의 용도 |
JP5134916B2 (ja) * | 2005-07-08 | 2013-01-30 | 持田製薬株式会社 | 心血管イベント発症予防用組成物 |
KR101465715B1 (ko) * | 2005-07-08 | 2014-11-27 | 모치다 세이야쿠 가부시키가이샤 | 심혈관 이벤트 발병 예방용 조성물 |
BRPI0717972A2 (pt) * | 2006-11-01 | 2013-11-12 | Pronova Biopharma Norge As | Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar) |
WO2008142482A2 (en) * | 2006-11-01 | 2008-11-27 | Pronova Biopharma Norge As | Omega-3 lipid compounds |
CA2667211A1 (en) | 2006-11-01 | 2008-05-08 | Pronova Biopharma Norge As | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar) |
BRPI0718393A2 (pt) * | 2006-11-03 | 2013-11-26 | Pronova Biopharma Norge As | Álcoois de ácido graxo |
WO2010018856A1 (ja) * | 2008-08-13 | 2010-02-18 | 持田製薬株式会社 | カンナビノイド受容体関連疾患の予防/改善または治療剤 |
EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
PT2395991E (pt) | 2009-02-10 | 2013-09-03 | Amarin Pharmaceuticals Ie Ltd | Utilização de éster etílico de ácido eicosapentaenóico para tratamento de hipertrigliceridemia |
NZ789295A (en) | 2009-04-29 | 2024-02-23 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
NZ627238A (en) | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
CN114053258A (zh) | 2009-06-15 | 2022-02-18 | 阿马里纳药物爱尔兰有限公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
FR2949063B1 (fr) * | 2009-08-11 | 2011-09-30 | Pf Medicament | Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale |
SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
EP2638903A4 (en) * | 2010-11-09 | 2013-12-04 | Mochida Pharm Co Ltd | GLYCEMIA ELEVATION SUPPRESSOR |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
JP2015522029A (ja) | 2012-06-29 | 2015-08-03 | アマリン ファーマシューティカルス アイルランド リミテッド | スタチン療法中の患者における心血管系イベントの危険性を減少させる方法 |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
CN112218630A (zh) | 2018-09-24 | 2021-01-12 | 阿马里纳药物爱尔兰有限公司 | 降低受试者的心血管事件的风险的方法 |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60248610A (ja) * | 1984-05-23 | 1985-12-09 | Nitsusui Seiyaku Kk | 糖尿病合併症の予防および治療剤 |
GB2218904A (en) * | 1988-05-27 | 1989-11-29 | Renafield Limited | Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid |
GB2223943A (en) * | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
-
2004
- 2004-03-02 BR BRPI0408006-8A patent/BRPI0408006A/pt not_active Application Discontinuation
- 2004-03-02 JP JP2006505440A patent/JP2006519244A/ja active Pending
- 2004-03-02 AU AU2004216856A patent/AU2004216856A1/en not_active Abandoned
- 2004-03-02 MX MXPA05009432A patent/MXPA05009432A/es unknown
- 2004-03-02 CN CNA2004800055600A patent/CN1756545A/zh active Pending
- 2004-03-02 WO PCT/EP2004/050238 patent/WO2004078166A2/en not_active Application Discontinuation
- 2004-03-02 CA CA002515328A patent/CA2515328A1/en not_active Abandoned
- 2004-03-02 EP EP04737282A patent/EP1603551A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2006519244A (ja) | 2006-08-24 |
AU2004216856A1 (en) | 2004-09-16 |
EP1603551A2 (en) | 2005-12-14 |
WO2004078166A2 (en) | 2004-09-16 |
CN1756545A (zh) | 2006-04-05 |
MXPA05009432A (es) | 2005-11-23 |
BRPI0408006A (pt) | 2006-02-14 |
WO2004078166A3 (en) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2515328A1 (en) | Use of omega-3-fatty acids in the treatment of diabetic patients | |
CA2362271C (en) | Essential fatty acids in the prevention of cardiovascular events | |
US10058521B2 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
ES2262741T3 (es) | Uso de acidos grasos poliinsaturados para la prevencion de accidentes cardiovasculares importantes. | |
KR20080094073A (ko) | 뇌졸중 재발 예방용 조성물 | |
AU2020203658A1 (en) | Administering compositions comprising docosapentaenoic acid | |
US20040235948A1 (en) | Treatment of diabetic patients with omega-3-fatty acids | |
US8114906B2 (en) | Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease | |
US20060009486A1 (en) | Composition and method for treatment and prevention of coronary artery disease | |
AU2005244483B2 (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
JP2007532605A5 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20080303 |